Levetiracetam (the human brand Keppra, and many generics) is one of the modern antiseizure medications veterinarians reach for when a dog's seizures are not controlled by — or cannot be treated with — the older standbys like phenobarbital or potassium bromide. It has become popular for good practical reasons: it works through a different mechanism than the legacy drugs, it is cleared mostly by the kidneys rather than the liver, it does not require routine blood-level monitoring, and its side-effect profile is comparatively mild. It is also, in veterinary use, entirely off-label — there is no veterinary-specific levetiracetam product approved for dogs or cats, so every prescription is a human drug used extra-label under veterinarian judgment.

This article is the levetiracetam guide for dog owners and veterinary teams: how it works, the dosing reality created by its short half-life, the constraint that extended-release tablets impose, the rule that you must never stop it abruptly, the interactions that change its dose, the advantage it has in liver disease, an honest look at the openFDA adverse-event data, and how it compares with phenobarbital. It is the drug-specific companion to the site's seizures in dogs workup and the potassium bromide page.

Quick answer

Levetiracetam is an off-label human antiseizure drug used in dogs. The immediate-release form is typically started at 20 mg/kg by mouth every 8 hours (with published ranges up to 60 mg/kg per dose); the extended-release form is dosed at 30 mg/kg every 12 hours but comes only in 500 mg and 750 mg tablets that cannot be split or crushed, so it is generally limited to larger dogs. Its short half-life — roughly 3–4 hours for immediate-release and 4.5–5 hours for extended-release — is the entire reason for the frequent dosing: the drug leaves the body quickly, and missing the schedule invites breakthrough seizures. Never stop levetiracetam abruptly — withdrawal can trigger seizures, including severe ones, so it must be tapered under veterinary direction. Phenobarbital and potassium bromide increase levetiracetam's clearance, so higher levetiracetam doses may be needed when used in combination; zonisamide does not. Because it is cleared mostly by the kidneys with minimal liver metabolism, it is a preferred antiseizure drug in dogs with liver disease.

What levetiracetam does (and how it differs from phenobarbital)

Most older antiseizure drugs work by broadly enhancing inhibition (GABA) or blocking sodium or calcium channels. Levetiracetam is different. It binds a specific synaptic vesicle protein called SV2A found on nerve terminals throughout the brain, and this binding is believed to dampen the abnormal, synchronized firing that defines a seizure — without directly acting on the classic GABA, sodium, or T-type calcium pathways the legacy drugs target. The practical consequence is a different side-effect and interaction profile: because levetiracetam does not go through the cytochrome P450 liver enzyme system and does not depend on hepatic metabolism, it neither causes the liver burden that phenobarbital can nor gets caught up in the same drug-drug interactions.

It is considered very safe across the published experience; adverse effects, when they occur, tend to be mild and include sedation, ataxia (a wobbly gait, usually in the first days of treatment), inappetence, and vomiting. Notably, levetiracetam has no loading dose and generally does not require routine therapeutic drug monitoring — the dose is typically titrated to seizure control rather than to a target blood level, which is a meaningful practical advantage over phenobarbital and bromide.

What is the levetiracetam dose for dogs, and why does the 4-hour half-life matter?

The defining pharmacokinetic fact about levetiracetam in dogs is its short half-life: about 3–4 hours for the immediate-release formulation (and about 3 hours in cats). That short half-life is the reason the immediate-release form has to be given three times a day — every 8 hours. A twice-daily immediate-release schedule would leave long stretches of the day with drug levels too low to suppress seizures, which is why adherence to the eight-hour interval matters more with levetiracetam than with almost any other daily veterinary drug. The published starting dose is 20 mg/kg by mouth every 8 hours, with the literature citing ranges up to 60 mg/kg per dose in some patients; many neurologists start at the lower end and titrate upward in roughly 20 mg/kg increments until seizures are controlled, side effects appear, or cost becomes limiting.

The extended-release formulation is the answer to the three-times-a-day burden, and it changes the schedule to 30 mg/kg every 12 hours — twice daily. The trade-off is real, though. A dog on extended-release levetiracetam still has drug levels that fluctuate substantially over the 12-hour interval (the elimination half-life of the extended-release form is about 4.5–5 hours, meaning levels swing significantly between doses), so even on the extended form, monitoring and sometimes individualized dose timing matter. The other constraint — and the one owners most often trip over — is tablet size.

The extended-release tablet sizing problem

This is the practical catch that determines whether extended-release is even an option for a given dog. Levetiracetam extended-release tablets are manufactured only in 500 mg and 750 mg strengths, and the prescribing information states they must not be chewed, broken, or crushed — breaking them destroys the extended-release mechanism and can cause the whole dose to release at once or, anecdotally, the tablet to pass through the gastrointestinal tract undigested.

Because the tablets cannot be split, the dose has to be delivered as a whole-tablet multiple of 500 or 750 mg. That works for larger dogs — a 30 kg dog getting roughly 1,000 mg every 12 hours is two 500 mg tablets, a clean fit — but it does not work for small dogs, where the smallest tablet is far too large a dose and cannot be divided. As a rule of thumb, dogs under roughly 15–16 kg (about 35 pounds) are usually limited to the immediate-release formulation, where tablets can be split and the dose matched to body weight. For small and toy breeds, and for any dog requiring precise small doses, immediate-release three times daily remains the standard. This sizing constraint is one of the most common reasons an owner is told their dog has to be on the more frequent schedule.

A veterinary neurologist quoted in the continuing-education literature puts the practical guidance bluntly: adhere to the eight-hour (immediate-release) or twelve-hour (extended-release) interval as closely as possible, because the short half-life means levetiracetam leaves the system quickly and the only way to keep a therapeutic level present at all times is to stick to the schedule. If an owner's daily routine makes three-times-daily dosing genuinely impossible, that is exactly when the conversation about extended-release — and whether the dog is large enough for it — happens.

Can levetiracetam be stopped suddenly, and what happens if a dose is missed?

This is the single most important safety rule on this page, and it applies to levetiracetam the same way it applies to any antiseizure drug: do not stop it suddenly. Abrupt withdrawal of an antiseizure medication can trigger seizures — including severe or prolonged seizures (status epilepticus) — even in a dog whose seizures had been well controlled. This is a withdrawal effect, not a reflection of whether the drug "worked."

The rule has direct implications for everyday adherence:

• A missed dose is not the same as stopping, but a pattern of missed doses in a short-half-life drug like levetiracetam creates exactly the kind of trough that invites a breakthrough seizure. If a dose is missed, the standard guidance is to give it as soon as remembered and then resume the normal schedule — but talk to your veterinarian about the specific instruction, because timing relative to the next dose matters.
• Running out of the medication is a common and avoidable cause of forced interruption. Because levetiracetam is a human generic dispensed through pharmacies, refills can hit insurance or pharmacy-timing friction; refilling several days before running out is the practical safeguard.
• Stopping for side effects or because seizures seem controlled must always be a veterinary-directed, gradual taper, not a cold stop. The decision to discontinue is also a clinical one: in well-controlled idiopathic epilepsy, antiseizure drugs are typically continued long-term, and any change is made deliberately and slowly.

The same logic applies to dose changes — increases, decreases, and switches between immediate- and extended-release formulations should be made with veterinary guidance, because the two formulations are not a simple milligram-for-milligram swap given their different release characteristics.

Drug interactions: phenobarbital and bromide raise the clearance

Levetiracetam's interaction profile is one of its advantages, but it is not interaction-free, and the most important interaction is with the other antiseizure drugs a dog may already be taking.

The key fact, confirmed by population pharmacokinetic studies in epileptic dogs: concurrent phenobarbital increases levetiracetam's clearance, lowering peak levels and overall exposure. The same effect has been described with potassium bromide. The practical consequence is that a dog on levetiracetam together with phenobarbital and/or bromide may need higher or more frequent levetiracetam doses to achieve the same seizure control — the classic "toy breeds and dogs on phenobarbital require proportionately higher doses" guidance from neurology rounds. Toy and small breeds in general may also need proportionately adjusted dosing.

The contrast that matters: zonisamide does not meaningfully alter levetiracetam pharmacokinetics in the published data, so a levetiracetam-plus-zonisamide combination does not carry the same dose-escalation pressure as a levetiracetam-plus-phenobarbital combination.

On the upside, because levetiracetam does not induce cytochrome P450 enzymes and is not protein-bound to any meaningful degree, it does not interfere with most other medications a dog might be on — a meaningful advantage over phenobarbital, which broadly induces liver enzymes and alters the disposition of a long list of co-administered drugs.

The liver-disease advantage

Because levetiracetam is excreted primarily unchanged by the kidneys and undergoes minimal hepatic metabolism (it does not rely on cytochrome P450), it is a preferred antiseizure drug for dogs in whom liver function is a concern. This matters in two specific populations.

The first is the dog with intrinsic liver disease — a patient who has suffered liver toxicosis from phenobarbital but still needs an antiseizure drug, or a dog whose liver enzymes make phenobarbital a poor choice. Levetiracetam sidesteps the hepatic burden because the liver is not the route of elimination. The second is the dog with a portosystemic shunt — an abnormal blood vessel that bypasses the liver — which can present with seizures related to hepatic encephalopathy; levetiracetam is favored in these patients precisely because impaired liver metabolism is not a limiting problem. (The site's note: dogs with portosystemic shunts and other structural causes of seizures are a different population from idiopathic epilepsy, and the diagnostic distinction matters — see the seizures in dogs workup.)

The other side of the renal-clearance coin: because the drug leaves through the kidneys, significant kidney dysfunction could affect levetiracetam handling, and a veterinarian will factor kidney function into dosing in a CKD patient. In practice this is a far smaller constraint than the liver burden phenobarbital imposes.

How does levetiracetam compare with phenobarbital?

The choice between levetiracetam and phenobarbital (or bromide) is a clinical one driven by the individual dog, but the trade-offs are concrete enough to be named. The comparison that owners find useful:

The honest summary a neurologist would give: phenobarbital remains a first-line option for many dogs with idiopathic epilepsy because of long experience, low cost, and the availability of serum-level monitoring, while levetiracetam is favored when liver health is a concern, when sedation must be minimized, when a drug with minimal interactions is wanted, or as an add-on when a first drug is not fully controlling seizures. Potassium bromide, now available as the FDA-approved KBroVet, remains another option; see the site's potassium bromide page.

Behavioral changes: what the evidence shows

A question owners specifically ask is whether levetiracetam changes a dog's behavior or personality. The peer-reviewed evidence — including a published study of behavioral changes under levetiracetam treatment in dogs — is that a meaningful subset of owners report negative behavioral changes, while sedation and ataxia are relatively uncommon and usually transient. Reported changes can include restlessness, irritability, or changes in interaction, and these are worth flagging to the prescribing veterinarian because they can influence whether the dose is adjusted or a different drug is considered. The openFDA data below show behavioral-disorder terms among the reported reactions, consistent with this signal.

This cuts against the casual framing of levetiracetam as "side-effect free." The more accurate statement is that its physical side effects (sedation, ataxia, GI upset) are usually mild and transient, while behavioral effects are the effect owners should watch for and report — and they are the effect most likely to be under-recognized because they are subtler than a wobbly gait.

The openFDA adverse-event signal (and how to read it)

VetMedGuide's deduplicated analysis of the FDA openFDA animal adverse-event dataset for levetiracetam yields 655 unique reports as of the June 2026 export (collapsed to one record per unique adverse-event report identifier). The breakdown:

• Species: Dog 621; Cat 32; with one human and one unspecified. It is overwhelmingly a canine signal, consistent with levetiracetam's predominant use in dogs.
• Outcomes: Recovered/normal in 158; ongoing in 244; outcome unknown in 147; euthanized in 67; died in 30; recovered with sequela in 9.
• Most frequently reported terms: "seizure" not otherwise specified (306), vomiting (74), death by euthanasia (68), lethargy/CNS depression (82 combined), ataxia (58), elevated ALT (36), tremor (47), behavioral disorder (34), lack-of-efficacy terms (71 combined), and increased seizure frequency (30).
• About 456 of the reports (about 70%) carried a "serious" flag.

The single most important caveat for interpreting these numbers — and the one most competitors omit — is that "seizure" as the top reported reaction term does not mean levetiracetam causes seizures. These are dogs who were put on levetiracetam because they have epilepsy or another seizure disorder. A seizure happening in an epileptic dog on levetiracetam reflects the underlying disease (or a lack of efficacy / breakthrough) far more often than it reflects a drug-induced event. This is the classic "confounded by indication" trap of passive pharmacovigilance in epilepsy: the population taking the drug is defined by the very events being reported. The honest reading is that the seizure, lack-of-efficacy, and increased-seizure-frequency terms together describe the disease population's experience (some dogs do not achieve control on levetiracetam), while the genuine drug-effect signal lives in the milder terms — sedation, ataxia, vomiting, behavioral changes — and in the rare outcome counts, which largely reflect the severity of refractory epilepsy rather than direct drug toxicity.

Three caveats apply to all of these counts, as they do for any openFDA analysis. The data are passive-surveillance reports, not incidence rates and not proof of causality. A report filed after a dog took levetiracetam does not establish that levetiracetam caused the outcome, because these dogs are often on multiple antiseizure drugs and have serious underlying neurologic disease. And the high "serious" flag rate and the death/euthanasia counts reflect the gravity of refractory epilepsy in the reported population, not a drug-specific mortality signal. This levetiracetam profile is part of the site's broader openFDA anti-infective and drug adverse-event analyses, where the dataset, deduplication, and passive-surveillance caveats are described in detail.

Is levetiracetam FDA-approved for dogs?

No veterinary levetiracetam product is FDA-approved for dogs or cats. As the Merck Veterinary Manual states plainly, levetiracetam "is not labeled for use in dogs and cats" but can serve as a first-choice antiseizure drug for animals not responding to phenobarbital, or for dogs not responding to bromides. Every prescription is therefore an extra-label use of a human drug, written under AMDUCA-style veterinarian judgment. This is the same off-label status as many commonly used veterinary medications (including gabapentin); it is not a safety flag in itself, but it is the reason there is no veterinary-specific label and no veterinary-specific dosing chart — the dosing comes from the peer-reviewed veterinary pharmacology literature and specialist consensus, applied to the individual patient by the prescribing veterinarian.

Frequently asked questions

Why does my dog need levetiracetam three times a day instead of once?

Because of the short half-life. The immediate-release form of levetiracetam is eliminated in about 3–4 hours in dogs, so by the end of an 8-hour interval the levels have fallen substantially. Giving it every 8 hours is what keeps enough drug in the system to suppress seizures around the clock. Once-daily dosing would leave the dog unprotected for most of the day. If three-times-daily dosing is genuinely impractical, the extended-release form (twice daily) is an option — but only for dogs large enough to take whole 500 mg or 750 mg tablets, which cannot be split.

Does levetiracetam cause behavior changes or aggression in dogs?

Behavioral changes are the side effect owners should specifically watch for. The published evidence shows a meaningful subset of owners report negative behavioral changes (such as restlessness or irritability) under levetiracetam, while sedation and ataxia are less common and usually transient. Overt aggression is reported rarely. Any notable behavioral change should be reported to the prescribing veterinarian, because it can influence whether the dose is adjusted or a different drug is considered.

Can levetiracetam be stopped suddenly if my dog seems better?

No — never stop levetiracetam abruptly. Sudden withdrawal of an antiseizure drug can trigger seizures, including severe or prolonged seizures, even in a dog whose seizures had been controlled. If levetiracetam needs to be stopped or changed — whether because of side effects, lack of efficacy, or apparent remission — it must be tapered gradually under your veterinarian's direction.

Is levetiracetam better than phenobarbital for my dog?

Neither is universally "better." Phenobarbital is a long-established first-line option with inexpensive cost and available serum-level monitoring, but it carries liver burden and broad drug interactions. Levetiracetam is favored when liver health is a concern, when minimal sedation and minimal interactions are wanted, when the dog cannot tolerate phenobarbital, or as an add-on for incomplete control. The choice is individualized based on the dog's seizure type, other health problems (especially liver and kidney function), the owner's ability to adhere to a three-times-daily schedule, and cost.

Sources

• Merck Veterinary Manual. "Epilepsy in Small Animals — Levetiracetam in Epilepsy" (dosing, half-life, off-label status, hepatic metabolism). https://www.merckvetmanual.com/nervous-system/epilepsy-in-small-animals/epilepsy-in-small-animals
• Merck Veterinary Manual (MSD). "Anticonvulsants for Treatment of Animals" (distribution, metabolism, elimination, half-life by species). https://www.msdvetmanual.com/pharmacology/systemic-pharmacotherapeutics-of-the-nervous-system/anticonvulsants-for-treatment-of-animals
• Today's Veterinary Practice. "Treatment Plans for Routine and Refractory Canine Epilepsy" (levetiracetam dosing, phenobarbital interaction, titration). https://todaysveterinarypractice.com/neurology/treatment-plans-for-routine-and-refractory-canine-epilepsy
• dvm360. "What's new, what's tried-and-true: an update on small animal seizure management" (levetiracetam IR/ER dosing, half-life, monitoring, cost). https://www.dvm360.com/view/what-s-new-what-s-tried-and-true-update-small-animal
• dvm360. "Coughs of the brain: Seizure control in dogs with idiopathic epilepsy" (comparative antiseizure drug table). https://www.dvm360.com/view/coughs-brain-seizure-control-dogs-with-idiopathic-epilepsy
• Beasley MJ, Boothe DM. "Disposition of extended-release levetiracetam in normal healthy dogs after single oral dosing" (ER 30 mg/kg q12h, half-life 4.5–5 h). Journal of Veterinary Internal Medicine, 2015; PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC4858031
• Rounds M, et al. "Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide" (phenobarbital increases clearance; zonisamide does not). PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC6189379
• Packer RMA, et al. "Assessment into the usage of levetiracetam in a canine epilepsy clinic." BMC Veterinary Research, 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC7146871
• Remedy Veterinary Specialists. "Keppra for Dogs and Cats" (specialty neurology dosing, withdrawal guidance). https://www.remedyvets.com/keppra
• VetMedGuide openFDA adverse-event analysis (animal adverse-event events dataset, June 2026 export; deduplicated by unique report identifier; passive-surveillance counts, not incidence). Method described in the site's openFDA adverse-event analysis.